Main uses of Desloratadin Actavis

Desloratadin Actavis is an antiallergic medication belonging to the class of non-sedating antihistamines. It works by blocking the action of histamine, a natural substance in the body that triggers allergic reactions. This medication is primarily used to manage symptoms associated with two distinct conditions: allergic rhinitis and urticaria.

Allergic Rhinitis

Desloratadin Actavis is indicated for the relief of symptoms associated with allergic rhinitis, which is an inflammation of the nasal passages caused by an overreaction to environmental allergens. These symptoms typically include:

• Sneezing: Frequent and repetitive episodes.
• Nasal discharge: A runny or itchy nose.
• Nasal congestion: A feeling of stuffiness in the nose.
• Ocular symptoms: Itchy, red, or watery eyes, as well as an itchy palate.

The medication is effective for both seasonal allergic rhinitis (often referred to as hay fever) and perennial allergic rhinitis, which occurs year-round due to triggers such as dust mites, pet dander, or mold.

Urticaria

Desloratadin Actavis is also used to alleviate symptoms of urticaria, commonly known as hives. This is a skin condition characterized by the sudden appearance of itchy red bumps or wheals. The medication helps to manage:

• Pruritus: Intense itching of the skin.
• Skin lesions: The size and number of hives or wheals on the body.

Benefits of Treatment

By inhibiting the effects of histamine, Desloratadin Actavis helps patients maintain their normal daily activities and improves sleep quality, which are often disrupted by persistent allergic symptoms.

One of the primary characteristics of this medication is its long-lasting effect, which typically allows for once-daily administration to provide relief throughout the day and night. Additionally, as a non-sedating antihistamine, it is designed to relieve symptoms without causing significant drowsiness in most individuals, allowing for the maintenance of mental alertness.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Desloratadin Actavis?

The population eligibility for this medicine is strictly defined by regulatory documents, which outline who is permitted to use the product and who is excluded or restricted.

---

Populations for Whom Use is Contraindicated

The medicine is absolutely contraindicated for patients with a known hypersensitivity to the active substance, desloratadine, its precursor, loratadine, or any other excipient in the formulation.

Age-Related and Pediatric Eligibility

The 5 mg film-coated tablet is officially approved for use in adults and adolescents aged 12 years and older. Safety and efficacy have not been established for infants below the age of 6 months. The tablet formulation is generally not recommended for children under 12 years.

Conditional Use and Restrictions

Use requires caution in adults with severe renal impairment or hepatic impairment, as official labeling indicates that drug clearance may be altered. Caution is also advised for patients with a medical or familial history of seizures.

Pregnancy and Lactation Status

Use is not recommended during both pregnancy (as a precautionary measure) and breastfeeding because the substance is known to be excreted into breast milk.

Interactions with other medicines and products

Desloratadine has a limited profile of clinically significant interactions documented in official regulatory labeling. All information presented here is based strictly on authoritative government sources and clinical trial data.

Drug–Drug Interactions and Exposure Modification

Co-administration with certain medicinal products results in a measurable pharmacokinetic interaction that increases the systemic exposure of desloratadine. Specific substances documented to increase plasma concentration ( C max and AUC) include Ketoconazole, Erythromycin, Cimetidine, Azithromycin, and Fluoxetine.

Official regulatory conclusions state that, despite these documented increases in exposure, no clinically relevant interactions were observed in clinical trials for these combinations. No specific medicine or substance is listed as a strictly contraindicated combination in the official labeling for single-ingredient desloratadine.

Interactions with Alcohol and Food

Alcohol (ethanol) does not appear to potentiate its performance-impairing effects according to controlled clinical trials. However, due to post-marketing reports of alcohol intolerance and intoxication, official documents advise caution with concomitant use.

Food does not have a clinically relevant effect on the absorption of the medicine, and desloratadine may be taken with or without food.

Administration Timing and Special Populations

There are no mandatory timing separation rules or requirements for administering this medicine apart from other products.

Patients with severe hepatic impairment or severe renal impairment may experience increased systemic drug exposure (AUC and C max) due to slower clearance, a factor noted in official regulatory information concerning specific patient populations.

The mechanism of action of Desloratadin Actavis (desloratadine) is centered on its role as a selective antagonist of the peripheral H1 histamine receptor. Histamine, an endogenous mediator, initiates various cellular responses by binding to and activating these receptors. Desloratadine competitively binds to the H1 receptor, thereby interfering with the initial signaling event mediated by histamine and preventing receptor activation.

Beyond this primary receptor blockade, desloratadine also engages in the broader modulation of inflammatory cascades. It regulates overactive cellular processes by interfering with the release of several other inflammatory mediators and cytokines from immune cells, such as mast cells and basophils. This reduces the impact of excessive mediator activity and contributes to the decreased magnitude of downstream physiological responses.

Pharmacologically, the drug is characterized by high selectivity for peripheral H1 receptors and a long plasma half-life. This results in prolonged, continuous receptor occupancy, which sustains the modulation of physiological parameters over a full 24-hour period.

The administration of Desloratadin Actavis is strictly through the oral route, utilizing either the 5 mg film-coated tablet or the 0.5 mg/mL oral solution form. The high-level usage principles are determined by age, physiological status, and the pattern of the underlying condition.

The standard adult dose for individuals 12 years of age and older is 5 mg Desloratadine, taken once daily. This consistent frequency establishes the required therapeutic schedule. The tablet may be administered with or without food and should be swallowed whole with water. For children, the dose is determined by age and must be measured precisely using a calibrated dosing device to administer the required 2.5 mg or 1.25 mg of the oral solution.

---

Use Pattern and Population Adjustments

The medicine's use is structured to accommodate the nature of the symptoms. For intermittent allergic episodes (symptoms present less than four days per week or for less than four weeks), the administration may be discontinued when symptoms resolve and reinitiated upon their return. In contrast, administration for persistent conditions, such as Chronic Idiopathic Urticaria, is generally continuous.

A specific dosing adjustment is required for patients with severe renal or hepatic impairment, where the recommended starting regimen is 5 mg every other day to accommodate altered drug clearance. If a scheduled once-daily dose is missed, it should be taken as soon as the patient remembers, but a double dose must not be taken to make up for the forgotten dose.

Research evidence / Overview of studies

This section summarizes key research findings related to Desloratadin Actavis. The information presented is based on clinical trials and published research.

---

Efficacy Findings

Studies have evaluated whether Desloratadin Actavis is associated with a reduction in the frequency and severity of symptoms linked to allergic rhinitis and chronic urticaria. The primary body of evidence is drawn from randomized, controlled trials (RCTs).

• Symptom Frequency: One large-scale trial reported findings that included a reduction in symptom flare-ups over the study duration.
• Severity: Research examining symptoms has indicated outcomes that include lower average severity scores in the group receiving the drug compared to the placebo group.
• Long-term Use: Follow-up studies explored the effect of sustained use, but evidence remains limited on definitive long-term outcomes.

---

Mechanism of Action (As Studied)

Research examined the drug's effect on specific pathways related to inflammatory and allergic responses.

• Receptor Targeting: Studies evaluated the drug's activity on specific receptors.
• Pathway Effect: Research evaluated the drug's effect on a specific and targeted pathway.

---

Important Considerations

Research findings relating to efficacy were observed in study participants. Individuals should consult with a healthcare professional regarding their treatment options. Study protocols included participants adhering strictly to prescribed instructions.

• Individual Response: Findings show variability in how different people respond to the medication.
• Adverse Events: Potential side effects identified in the studies are addressed in a separate section.

Common questions about Desloratadin Actavis (FAQ)

---

Q: How quickly does Desloratadin Actavis usually start working for allergy symptoms?

Studies and official information indicate that the onset of action generally begins within 1 to 2 hours after taking the medicine. The drug typically reaches its highest concentration in the body in approximately 3 hours.

---

Q: How long does the effect of Desloratadin Actavis last?

Due to its pharmacological characteristics, including a long plasma half-life, the medicine is described as providing continuous relief that lasts for a full 24-hour period. This characteristic supports its use as a once-daily medicine.

---

Q: Can Desloratadin Actavis cause insomnia or trouble sleeping?

Official documents list insomnia (trouble sleeping) as a potential side effect, though it is classified as a very rare occurrence, meaning it may affect less than 1 in 10,000 people. Sleepiness (somnolence) is also listed as a less common side effect.

---

Q: Is Desloratadin Actavis generally recommended for breastfeeding women?

Official regulatory documents indicate that use of this medicine is not recommended during breastfeeding. This cautionary measure is advised because the active substance, desloratadine, is known to be excreted into breast milk.

---

Q: Can people with kidney problems use Desloratadin Actavis?

Use requires caution in patients with severe kidney problems. Official labeling indicates that a dose adjustment is generally applied for individuals with severe renal impairment to accommodate the body’s altered rate of drug clearance.

---

Q: What is the risk of Desloratadin Actavis interacting with alcohol?

Controlled clinical trials have found that alcohol does not appear to increase the performance-impairing effects of the medicine. However, official documents suggest caution with concomitant use due to post-marketing reports of alcohol intolerance or intoxication in some patients.

---

Q: Is it necessary to take Desloratadin Actavis at the same time every day?

The medicine is intended for once-daily use to provide 24-hour symptom relief. While regulatory labeling does not strictly mandate a specific time, taking it routinely is a practice that can help maintain consistent therapeutic effects.

---

Q: Does Desloratadin Actavis contain lactose or gluten?

The film-coated tablet formulation contains the excipient lactose (as monohydrate). Official warnings suggest that patients who have rare hereditary problems with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption review the full excipient list.

---

Q: Are there different strengths of Desloratadin Actavis available?

The medicine is typically available in two main forms and strengths: the 5 mg film-coated tablet and the 0.5 mg/mL oral solution. These different forms are provided for various patient needs.

---

Q: What is the main reason Desloratadin Actavis is prescribed?

The fundamental purpose of the drug is described in official product information as acting as a selective H1-receptor antagonist. This means it works to block the effects of histamine, a key chemical messenger that triggers the physical symptoms of allergic reactions, to provide generalized allergy relief.

---

Q: Is Desloratadin Actavis suitable for treating both indoor and outdoor allergies?

The medicine is officially indicated for relieving symptoms associated with both seasonal allergic rhinitis (often linked to outdoor allergens like pollen) and perennial allergic rhinitis (often linked to year-round or indoor allergens like dust mites).

---

Q: Is there an age limit for who can use Desloratadin Actavis?

The 5 mg film-coated tablet formulation is approved for use in individuals aged 12 years and older. The safety and efficacy of the medicine have not been established for infants below the age of 6 months.

---

Q: Does Desloratadin Actavis help with congestion as well as sneezing?

Official product information suggests the medicine has properties that may reduce nasal congestion and related symptoms, in addition to addressing non-nasal symptoms like sneezing, runny nose, and itching.

---

Q: Can Desloratadin Actavis cause weight changes?

Official regulatory documents list weight increased as a potential undesirable effect. However, the frequency of this occurrence is classified as not known because it cannot be estimated from the available data.

---

Q: Is Desloratadin Actavis available over the counter in some places?

Official sources indicate that desloratadine-containing products are available over-the-counter (OTC) in certain countries or regions. However, the prescription status of the medicine may vary significantly depending on local regulatory policy.

---

Q: What research exists about Desloratadin Actavis use in older adults?

Official drug monographs often state that dosage adjustment based on age is generally considered not necessary for older adults. This indicates that the medicine’s use and dosing principles are generally aligned with those for the general adult population.

---

Q: Can Desloratadin Actavis cause changes in mood?

Official documents describe psychiatric disorders as a potential effect, with side effects such as hallucinations and psychomotor hyperactivity reported very rarely in post-marketing surveillance.

---

Q: How is the safety of Desloratadin Actavis monitored by health authorities?

The safety of the medicine is continuously monitored by health authorities through a formal system known as pharmacovigilance or post-marketing surveillance. This involves the ongoing collection and review of reports detailing adverse effects submitted by healthcare professionals and patients after the drug has been made available.

---

Q: Is Desloratadin Actavis known to interact with grapefruit juice?

Clinical data reported in official drug labeling indicates that consuming grapefruit juice did not have a clinically relevant effect on the bioavailability (the amount absorbed into the bloodstream) of desloratadine.

---

Q: Why might a patient need to take Desloratadin Actavis every day?

Continuous daily intake is generally described in official documents for the management of persistent allergic conditions. These are defined as conditions where symptoms are present for four or more days per week and for longer than four weeks, requiring sustained relief.

---

Q: What common food interactions, if any, are listed for Desloratadin Actavis?

Official documentation states that food does not have a clinically relevant effect on the absorption of the medicine, and no specific common food interactions are typically listed in the regulatory labeling.

---

Q: Is Desloratadin Actavis commonly used for seasonal allergic conjunctivitis?

The medicine is indicated for the relief of general symptoms associated with allergic rhinitis. This includes addressing symptoms that affect the eyes, such as itchy, watery, or burning eyes, which are components of allergic conjunctivitis.

Official Storage and Disposal Instructions

Desloratadine Actavis must be stored strictly according to the conditions defined in the regulatory labeling.

Storage Conditions

Film-coated tablets packaged in blisters do not require any special temperature conditions, meaning they are stable at normal room temperature. The medicine must be kept out of the sight and reach of children as a mandatory safety requirement.

Specific packaging constraints apply to protect product stability:

Item	Constraint
Protection	Store in the original container.
Bottled Presentations	The bottle must be kept tightly closed in order to protect from light.

Disposal

For the discarding of unused or expired Desloratadine Actavis, no special requirements for the medicinal product itself are listed in the official documentation. Disposal must adhere to all local requirements for pharmaceutical waste.